Active Immunotherapy in cancer – Current Status

Bakulesh Khamar*
R&D Department, Cadila Pharmaceuticals Limited, India

*Corresponding author: Bakulesh Khamar, R&D Department, Cadila Pharmaceuticals Limited, “Cadila Corporate Campus, Sarkhej - Dholka Road, Bhat, Ahmedabad, Gujarat, India-382210

Submission: February 21, 2018; Published: March 28, 2018

Abstract

Immunotherapy is a fourth pillar in cancer management after surgery, radiotherapy and chemotherapy. Active immunotherapy works by inducing antigen specific immune response following its administration while checkpoint inhibitor works by reducing tumor induced immunosuppression and thereby utilizing pre-existing immune response. Adoptive cell therapy (ACT) is a type of personalized therapy wherein cells are harvested from a patient, expanded and reintroduced. The T cells are genetically modified in chimeric antigen receptor T cell (CAR-T) therapy while tumor infiltrating cells are used in in ACT and dendritic cells are used in dendritic cell (DC) vaccine. Vaccine induces T cell response against the antigen of interest. T cells available following single administration are higher in ACT compared to vaccine approach. CART cells are found useful in refractory large B-cell lymphoma and refractory large B-cell precursor acute lymphoblastic leukemia. ACT is found useful in melanoma. Vaccines are approved for melanoma as a monotherapy and for non-small cell lung cancer in combination with chemotherapy.

Keywords: CAR-T therapy; ACT; Dendritic cell vaccine; Cancer vaccine; CD8+T cells; Active immunotherapy

Introduction

Cancer development and progression is associated with inability of immune system to recognize cancer cells as foreign and destroy it. This is done mainly by cell mediated immune response. Cells mediated immune response play a critical role in development and progression of cancer. Effective utilization of cell mediated immune response holds promise to cure cancer. Early evidence indicating importance of immune cells came from histopathological evaluation of tumor infiltrating immune cells and their role in prognosis [1-7]. It suggests correlation between amount and type of immune cells with outcome is well documented [3,7-13]. Increase in Th1-type signature is associated with good clinical outcome in many different tumor types including colorectal cancer, melanoma, head & neck, breast, bladder, urothelial, ovarian, renal, prostate, hepatocellular cancer and lung cancer [10,14,15]. CD8 cell preponderance is associated with better outcome [12,16-18]. CD45RO+ T cells infiltration is known to improve outcome in esophageal (also squamous) cancer, colorectal cancer, ovarian cancer, gastric cancer, hepatocellular cancer [19].

NK cell infiltration is also described as a positive prognostic factor [20]. Preponderance of immunosuppressive immune cells like FOXP3+ Treg, MDSCs are associated with poor prognosis including worse OS [17,21-25]. Relative proportion of either Tregs or MDSCs cells (immunosuppressive cells) to CD8+ T effector cells is a strong prognostic indicator for responses to chemotherapy/immunotherapy and patient outcomes [26].

Recognizing importance of immune mechanism in cancer, “Immunoscore,” is designed for better prognostication. It is found to superior to the conventional TNM classification in colorectal cancer, Non- small cell lung cancer (NSCLC), hepatocellular cancer and gastric cancer [27-32]. In NSCLC immunoscore using CD45RO+ cells and CD8+ T cells predict outcome in Squamous NSCLC but not in adenocarcinoma. In Squamous NSCLC higher score is associated with better outcome compared to lower score (P<0.001). The hazard ratio (HR)/ (benefit) increases with the stage of disease. It is 4.35 (p=0.012) for stage I, 8.24 (p<0.001) for stage II and 9.52 (p=0.002) for stage III [19]. Immunoscore is associated with

I. Rate of response to treatment
II. Survival in patient
III. Responding to treatment
IV. Not responding to treatment

Based on presence or absence of Tumor Infiltrating lymphocytes (TIL) and checkpoint protein tumor classification is proposed. Tumors without TIL and checkpoint protein may benefit from active immunotherapy while tumors with checkpoint protein may benefit from checkpoint inhibitor. Both may be synergistic when TIL is absent and checkpoint protein is present or has a potential following active immunotherapy [6].
The importance of immunotherapy became evident and came to limelight with approval of checkpoint inhibitors. Immunotherapy is now considered fourth pillar of cancer management following surgery, radiotherapy, chemotherapy. Approved checkpoint inhibitors work by on immune suppressive arm by removing barriers to T cell activation to enhance preexisting immune response. Active immune therapy in general works by activating host immune response to a particular antigen/s. Such an immune response is also known as adaptive immunity and is provided by lymphocytes. Each person possesses over 1011 lymphocytes [34] with T-cells making around 80% of it. T cells possess receptors to recognize antigen and generate adaptive immune response against it. To generate response T cells needs co-stimulation (second signal) besides antigen recognition (first signal).

In any case, the correlation between macrophage density and patient survival is less significant than that of T cells, particularly CD8+T cells [16].

Approval of Axicabtagene ciloleucel for large B cell lymphoma in adults and tasiglenlecleucel for Refractory large B-cell precursor acute lymphoblastic leukemia in 2017 by US FDA has rekindled interest in active immunotherapy. Both are personalized CAR T-cell therapy. Both provide objective response rate (ORR) of more than 80% (Axicabtagene ciloleucel - 82% [35] and tasiglenlecleucel - 81% [36]) which seems to be durable like checkpoint inhibitor at this early stage.

**Efficacy of Active Immunotherapy Depends on Antigen, Effectors Function and Tumor Micro Environment**

**Antigens**

Antigens are substances (mainly proteins, polysaccharide, and peptides) found in tumor cells which are capable of generating activation (first) signal required for cell mediated immune response. Absence of antigen expression by tumor is associated with lack of response. Whole cells, cell lysates are also used to provide antigens. T cell infiltration is required for the efficacy of immunotherapy proportional to antigen expression [37]. Antigen expression is decreased by deacetylation or hypermethylation and can be increased by use of appropriate therapeutic agent like azacitidine [37].

Loss of antigen expression is associated with adaptive resistance to active immunotherapy as seen with CAR-T cell therapy [36]. Antigens expressed by tumors can be classified into following major groups [5,34].

**Over expressed normal proteins**: They are also named Tumor associated antigen. They are usually expressed at low levels in normal tissues but over expressed in cancer tissues (e.g., HER2, carcinoembryonic antigen (CEA) or non-mutated p53); non-mutated differentiation antigens (e.g., MART-1, over expressed in melanoma and found in normal melanocytes but not in other cells)

**Cancer-testis antigens (CTA)**: CTA are expressed by non-mutated genes during fetal development, then silent in normal adult tissues and reactivated in cancer cells across multiple malignancies (e.g., MAGE and NY-ESO).

**Mutated antigens or neoantigens**: They are also called tumor specific antigens and are found only in tumors [38]. They are caused by non-synonymous mutations or encoded by viral genes in tumors of viral origin and are unique to a single tumor or shared by a group of tumors (e.g., BRAF with the V600E mutation in melanoma and other solid tumors, or EGFR viii in glioblastoma).

**Effector function**

Effect or function measures strength of cell mediated immune response to kill tumor cells. It can be performed ex-vivo or in-vivo. It depends on type of immune cells, number of immune cells, affinity of immune cells and duration for which immune cells are available.

**Type of immune cells**: Activated antigen specific CD8+ cells are mainly responsible for killing of tumor cells [39]. CD4+ cells provide help to CD8 cell. They have minimal potential for killing tumor cells. T cells in earlier stage of differentiation have better efficacy and resistance in tumor compared to terminally differentiated [37].

**No. of immune cells**: concentration of activated antigen specific CD8+ T cells determines the efficiency with which these cells kill antigen-expressing target cells [39]. Increase in no. of CD8+ cells post therapy is associated with efficacy of vaccine [39] as well as its combination with checkpoint inhibitors [38]. Acritical concentration of activated antigen specific CD8+ T cells in relation to tumor burden is required for efficacy [39]. Responders to tasiglenlecleucel (CAR T-cells) had higher Cmax 36,100 copies/mcg of CAR T-cells compared to nonresponders 20,900 copies/mcg [36]. Fold change in activated antigen specific CD8+ T cells in relation to tumor burden following therapy is associated better ORR, PFS, and OS even with checkpoint inhibitors [23].

**Affinity of immune cells towards antigen bearing tumor cells**: Besides type and number of cells, affinity of activated antigen specific immune cells determine killing kinetic of immune cells in tumor bed [38]. Low affinity is associated with poor outcome [40]. It also depends on amount and type of antigen expressed by tumor cells. Tumors with low immunogenicity are counterproductive [40].

**Duration for which immune cells are available/persistence**: Duration for which activated antigen specific immune cells are available is also important for response to active immunotherapy [39], [40]. Longer duration increases chance of response. With tasiglenlecleucel (CAR T-cells), T1/2 in responders was 23.0days compared to 3.6days for non-responders [40]. T last median was 168days for responder’s vs 49days for non-responders [40].

**Time to achieve peak no. of cells**: Shorter time is associated with better prognosis compared to longer time [36]. With tasiglenlecleucel (CAR T-cells) Tmax of 10days was associated with response to therapy while Tmax of 20days was seen in non-responders [36].
Tumor microenvironment

Hostile tumor microenvironment (TME) to anti-tumor immune response is associated with tumor growth and its spread. TME comprise of cancer cells, tumor educated stromal cells, infiltrating immune cells and tumor vasculature. Cancer cells play a major role in initiation of immunosuppressive changes in initial stages of cancer development which is maintained and potentiated by stromal cells and infiltrating immune cells. Immune changes brought about by cancer cell include (a) impaired T-cell immunologic synapse function through F actin [41] (b) apoptosis of T cell and (c) promotion of Treg by tumor exosome [42]. Cancer cells change profile of stromal fibroblasts to cancer associated fibroblasts (CAF). CAF are major component of stroma and account for more than 90% of cells in tumors like pancreatic cancer [43]. CAF from advanced tumor upregulates TGF-beta and induces immunosuppressive environment including recruitment of immune cells and their conversion to immunosuppressive cells [44]. CAF are also involved in metastasis [45]. They secrete angiogenesis factors like VEGF, FGF, SDF-1 and PDGF [46]. CAF resist killing of tumor cells by various therapeutic agents by [46] including (a) expression of MMP1, MMP2, MMP9, BCL-XL. (b) providing support to stem cells (c) inducing low pH of environment, (d) increased hyaluronan production, (e) increased interstitial fluid pressure etc. of CAF in stroma is inversely proportional to survival in colorectal cancer [46].

Cancer cells are known to divide rapidly, have very high cell density and high metabolic rate with relative hypoxia leading acidic microenvironment as tumor increases in size. Changes in immune profile [42,47] due to low pH include (a) loss of cytolytic activity by tumor specific cell: T and NK cells tend to lose their function and undergo a state of mostly reversible energy followed by apoptosis, (b) accumulation of immunosuppressive cells like myeloid cells and regulatory T cells, (c) secretion of immunosuppressive cytokines.

Tumor is highly vascular but vasculature is known to dysfunctional and limits exchange beyond tumor including infiltration of immune cells and cytokines. Thus cancer cells through their direct and effect on immune cells and through changes in stroma is associated with immune suppression making it difficult for active immunotherapy to be effective in cancer management.

In general a solid tumor like melanoma contains 3-5x10^8 cells/gm [48] and for its eradication >10^7 melanoma (tumor) antigen specific CD8 cells/g of melanoma for >8days is required [39].

Generating such a large number of antigen activated CD8 cells within body is a herculean task and is one of the reason for absence of tumor response with vaccine approach in established tumors. To overcome limitation, immune cells are expanded in vitro prior to reintroduction in a personalized approach. The amount of CAR T-cells infused is >10^8 for adults and for tumor infiltrating cells is for vaccine approach to be successful, it needs support from other therapy in management of advanced tumors [34].

Active immunotherapy comprises mainly two types of therapy

1. Large no. of activated immune cells are introduced as a therapy. This is currently a personalized approach and comprise of autologous cell transfer after expansion

CAR T-cell therapy

Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs)

Dendritic cell vaccine

2. Vaccines
   Approved Products
   A. T-VEC
   B. CADI-05
   3. Their Vaccine candidates
      A. Allogenic cell based vaccine
      B. Protein/peptide based vaccines
      C. Viral vector based vaccines

CAR T-cell therapy

The chimeric antigen receptor T cell (CAR-T) therapy involves leukapheresis for the removal of peripheral-blood T cells from a patient, followed by in vitro activation, genetic modification to express a Chimeric Antigen Receptor (CAR) on their cell membrane, and expansion of the T cells under Good Manufacturing Practice conditions, and finally the infusion of the cells back into the patient so they will attack cancer cells [49]. CAR-T cells are expected specifically to localize within tumor and eliminate tumor cells by interacting with the antigens expressed on tumor cell surface. First generation CART-T had antigen to induce activation signal and provided transient T cell activation. Subsequent CART-T cells also induces co-stimulatory signal [50].

Table 1

<table>
<thead>
<tr>
<th>Therapy</th>
<th>ORR</th>
<th>CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory large B-cell lymphoma</td>
<td>Asicbatagene ciloleucel [51]</td>
<td>82%</td>
</tr>
<tr>
<td>Refractory large B-cell lymphoma</td>
<td>CTL 019 [52]</td>
<td>63%</td>
</tr>
<tr>
<td>Refractory large b cell precursor acute lymphoblastic leukemia</td>
<td>Tisagenlecleucel [40]</td>
<td>81%</td>
</tr>
</tbody>
</table>

Asicbatagene ciloleucel and tisagenlecleucel are approved CAR T-cells [49]. Both contain CD19 directed genetically modified autologous T cells to express second-generation anti-CD19 CARs. CD19 is an antigen found in B-cell malignancies, which include several forms of lymphoma and leukemia. Major difference between two is costimulatory domain. In asicbatagene ciloleucel
costimulatory domain is C28 while it is 4-1BB in tisagenlecleucel. CTL019 is another advanced CAR T-cell therapy evaluated for B cell lymphoma. CAR T-cell therapy achieves complete response in more than 55% of treated patients (Table 1).

Unlike checkpoint inhibitors, CAR T-cell therapy (activated antigen specific cells) is administered once and it quickly induces response. Axicabtagene ciloleucel induces response with a median time to response - 1 month (range 0.8 - 6 months) [51]. Partial responses are not durable (2.1 month) but complete responses seem to be durable [Label - FDA]. OS with tisagenlecleucel is 90% at 6 months 76% at 12 months again indicating durability of response [40]. Recurrence is associated with loss of antigen (CD19) in 15 of 22 indicating loss of antigen as a major cause for acquired immune resistance. Both approved CAR T- cells and CAR T-cells in general are associated with severe side-effects, such as neurotoxicity and cytokine release syndrome leading to death. A neurologic toxic effect most commonly includes encephalopathy, confusion, and tremor. The cytokine-release syndrome most commonly includes fever, hypoxia, and hypotension. Cytokine storm is attributed to large no. immune cells infused. The majority of these side effects are reversible, with no clinical sequelae.

Attempts are made to develop improved CAR T cells with reduced side effect or efficacy.

A. Reducing side effects: Switchable CAR T cells and use of gamma delta T cells as autologous cells to produce CAR T-cell appear most promising CAR T cells with reduced side effect.

I. Switchable CAR T cells: Switchable CAR T cells are being evaluated to decrease on target, off tumor side effect profile. The Switch molecules are comprised of tumor targeting antibody or small molecule and second moiety which selectively binds to CAR and not endogenous receptor. Switchable CAR T cells are activated by administration of tumor targeting antibody or a small molecule [53,54]. Rapamycin and tacrolimus are two small molecules being evaluated [55]. CAR T cells get activated in presence of rapamycin. They are not activated when rapamycin is not available.

II. CAR T cells with gamma delta T cells: Use of gamma delta T cells , instead of alpha beta T cells, to generate CAR T cells is being evaluated [56,57]. Gamma delta T cells possess unique features such as direct antigen recognition, lack of alloreactivity, and ability to present antigens [57]. They are expected to have enhanced cytotoxicity while retaining their ability to migrate to tumor and act as antigen-presenting cells to prolong the intratumoral immune response [56]. They are expected to have reduced side effect profile as they selectively target cancer cells without attacking healthy cells. They might find use in management of solid tumors as they can present antigens.

B. Improving efficacy

I. Overcoming immunosuppression: Persisting CAR-T cells following infusion of CAR-T cells, have decreased activity compared to pre-infusion CAR-T [58, 59]. Decreased activity is associated with expression of pd-1 and co-inhibitory receptor CD160. Expressions of immunosuppressive markers are also associated with primary and secondary failure of CAR-T therapy. They are also considered main reason for poor response in chronic lymphocytic leukemia and solid tumors. Combinations with checkpoint inhibitors are being evaluated. Efforts are made to use CRISP technology to incorporate checkpoint inhibitor into CAR-T cells [60] or generate CAR-T cells which do not express PD-1 under any circumstances [61]. CAR-T cells targeting to T-cell receptor alpha constant locus. TRAC -CAR T cells Current production technology for CAR T-cells production is associated with suboptimal yield and weak activity. They decrease in no. over time and have increased exhaustion markers in persistent cells [58] resulting in decreased efficacy. TRAC-CAR T cells have uniform CAR expression in peripheral blood T cells and better efficacy resulting in better tumor control (greater response and prolonged median survival) in animal studies [62]. This is associated with persistence of activated TRAC-CAR T cells over time and absence of de-novo expression of exhaustion markers (2% vs 50% on day 17) [62].

C. Scalable of the shelf product

Current therapy needs autologous T cells to be harvested, modified and expanded, making this therapy time and resource consuming. Efforts are made to use allogenic T cells so that therapy can be made readily available. The challenge is to avoid graft vs. host disease. CRISPR technology is evaluated for knocking out the TCR and HLA genes to bypass GvHD [59].

D. CAR-T cells for solid tumors: Currently CAR T-cell therapy is limited to hematological malignanxx

i. NKR-2: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3ζ signaling [63]. It binds eight different ligands expressed on the cell surface of above 80% of solid and hematological malignancies which are normally absent on non-neoplastic cells. In preclinical studies, NKR-2 demonstrated long-term antitumor activity towards a breadth of tumor indications, with maximum efficacy observed after multiple NKR-2 administrations. Importantly, NKR-2 targeted tumors cells and tumor neovascularule and the local tumor immunosuppressive microenvironment. It does not need pre conditioning.

ii. Anti TAA (tumor associated antigen) CAR T cells: Efforts are made to target tumor associated antigens like EGFR, human epidermal growth factor receptor 2 (HER2), mesothelin (MSLN) MUC 16 etch for use in solid tumors [63]. In early clinical trials they appear safe and able to generate immune response. The response rate is not good [63]. This can be attributed to lack of TAA, inefficient trafficking of CAR-T cells, hostile micro environment.

Adoptive cell transfer therapy (ACT) of tumor-infiltrating lymphocytes (TILs)

Some TILs exhibits specific tumor lysis ability without killing normal cells both in vitro and in vivo. TILs are predominantly T cells with heterogeneous phenotypes that contained effector cells, and
memory cells, with most of them possessing specific tumor antigen recognizing ability. Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) involves isolation of TILs with antitumor activity, their expansion and re-infusion. [64]. Lymphodepletion before ACT is an important component of the treatment because it eliminates T regulatory cells and eliminates lymphocytes, which compete with the transferred cells for homeostatic cytokines such as interleukin 7 (IL7) and IL15 [64].

Current culture technique for T cell expansion allows, more than 1011 cells to be transfused [64,65]. Clonal repopulation of T cells directed against over expressed self-derived differentiation antigens, in combination with chemotherapy and high doses of IL-2, led to tumor regression in patients with metastatic melanoma [66]. Following infusion, TIL initially accumulates in the lungs for up to 24 h and then gets deposited in tumor sites [67].

Clinical responses are associated with (a) amount of tumor-resident CD8+ T lymphocytes targeting tumor-specific antigens [68,69] and depends on [70] (b) transfusion of younger phenotype cells [65], (c) cells with shorter doubling times, (d) higher cytotoxic capacity [71] or (e) higher GM-CSF secretion [65,72]. Nevertheless, analyses of neoantigen specific T-cell responses in melanoma patients treated by ACT demonstrated that the T-cell-recognized neoantigens can be selectively lost over time emphasizing the importance of targeting broad TCR recognized neoantigens to avoid tumor resistance [73].

ACT of TIL is mainly used for treatment of melanoma. It is possible to achieve ORR of 50% [64] and CR rates of 24% in both groups and median OS of 38.2 months [74].

It is also used in treatment of other tumors like colorectal cancer [65], hepatocellular cancer [75] with good outcome. Progression or recurrence is associated with loss of antigen expression by tumor [65].

The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas [64].

Application of this therapy to other solid tumors is always not possible as some tumors, “immune-desert tumors” or “cold tumors,” may have no or occasional TIL or TIL may display an exhausted state.

Dendritic cell (DC) vaccines

This is a personalized vaccine approach using extremely efficient antigen presenting properties of dendritic cells for induction of T cell immunity. In this approach, DCs are isolated from the patients’ peripheral blood mononuclear cells (PBMC), loaded with tumor antigens ex vivo, activated, and then re-infused back into the patient [76-78]. This approach has been evaluated in various academic centers for management of advanced cancers with some modest improvement in outcome. Sipuleucel-T is the first dendritic vaccine approved by US FDA in 2010 for treatment of metastatic prostate cancer as it improved survival by four months without response (tumor shrinkage) in any patients. The vaccine is prepared by culturing dendritic cells isolated from patients with a fusion protein PA2024, consisting of PAP (Protein found in prostate cancer but not in normal prostate tumors) linked to a granulocyte-macrophage colony-stimulating factor (PAP-GM-CSF). These activated APCs are eventually infused back into the patient.

Vaccine

A. Approved Products

1. Talimogene laherparepvec (T-vec) (Oncolytic Virus Vaccine): Oncolytic virus vaccine uses Oncolytic viruses which are native or attenuated viruses that selectively replicate in cancer cells lyse them and induce host antitumor immunity [79]. It harbors low levels of protein kinase R (PKR) and dysfunctional type-I IFN signaling elements [79]. It generates tumor-specific Immunity immune response probably by direct tumor cell lysis, release of soluble tumor antigens, and danger-associated molecular factors.

Talimogene laherparepvec (T-vec) contains genetically modified herpes simplex virus, type 1 and is approved for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Its administration is associated with increase in activated CD8+ T cells (CD3+, CD4+, HLA-DR+) 25-28 in peripheral from baseline by 1.51-fold, (4 weeks), 1.65-fold, (6 weeks), respectively [80]. Increases in activated CD8+ T cells seemed to correspond with patient response [80].

Efficacy and safety: Durable response rate (DRR), defined as the percent of patients with complete response (CR) or partial response (PR) maintained continuously for a minimum of 6 months, was 16.3% [81]. The median time to response was 4.1 (range: 1.2 to 16.7) months. T-VEC efficacy decreases with advanced disease stage IIIB, IIIC is 33% and for IVM1a is 16%. It is 24% for treatment-naive patients. T-VEC resulted in complete resolution of lesions in 47 % of injected lesions, 22 % of uninjected non-visceral lesions and 9 % of visceral lesions [82]. Median OS was 23.3 months with T-VEC versus 18.9 months with GM-CSF (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P = .051) with better OS in patients with stage IIIB, IIIC and 52% of uninjected [80]. Complete response was identical in both groups (31% vs.39%) [80].

Combination with checkpoint inhibitors:

Iplimunab: Combining it with ipilimumab improved response rate (irRC) to 50% (95% CI, 26.0 to 74.0) with DRR in 44% and CR in Four patients (22%) [80]. Responses were seen 74% of injected and 52% of un.injected [80]. Complete response was identical in both groups (31% vs.39%) [80].

Pembrolizumab: Combination therapy with pembrolizumab [83] improved objective response rate to 62%, with a complete response rate of 33%. Patients who responded to combination...
therapy had increased CD8+T cells, elevated PD-L1 protein expression, as well as IFN-γ gene expression on several cell subsets in tumors after talimogene laherparepvec treatment [83]. Response do not appear to be associated with baseline CD8+ T cell infiltration or baseline IFN-γ signature [83].

Response to therapy is better with combination therapy. It is best with anti PD-1 therapy. These findings suggest that oncolytic virotherapy may improve the efficacy of anti-PD-1 therapy by changing the tumor microenvironment [83]. Some of the viruses being evaluated in various cancers as virus vaccine include [79]:

a. Adenovirus: Bladder cancer, ovarian cancer, prostate cancer, head and neck cancer, sarcomas, NSCLC, glioblastoma
b. Coxsackie virus: Melanoma, breast cancer, prostate cancer
c. HSV-1: Melanoma, breast cancer, head and neck cancer, pancreatic cancer
d. Measles virus: Ovarian cancer, glioblastoma, multiple myeloma
e. Newcastle disease virus: Glioblastoma Type I IFN and Bcl-2
f. Parvovirus: Glioblastoma
g. Poliovirus: Glioblastoma
h. Poxvirus: Head and neck cancer; hepatocellular carcinoma, melanoma, colorectal cancer
i. Reovirus: NSCLC, ovarian cancer, melanoma, head and neck cancer
j. Seneca valley virus: Neuroblastoma, lung cancer
k. Vesicular stomatitis: Virus Hepatocellular carcinoma

II. CADI-05

CADI-05 induces cell mediated immune response against Desmocollin-3 (DSC3) expressing tumors [84,85]. DSC3 expression is used to differentiate Squamous NSCLC from adeno variety of NSCLC [86]. It is also expressed by ovarian cancer, melanoma, colorectal cancer, bladder cancer and [87]. In DSC3 negative epithelial tumors, it can be expressed by appropriate therapy like radiotherapy, chemotherapy, targeted therapy [87]. CADI-05 induces antitumor response through IFN-gamma secreting CD8+T cells [88] by increasing tumor infiltrating activated immune cells and reducing intratumoral immunosuppressive cells [89].

In randomized control clinical trial in advanced NSCLC, its combination with chemotherapy, it improved response rate by 10% (47% vs 37%) with the improved OS by 17.48% at the end of 1 year [84]. The benefit (Hazard ratio) more marked in patients with better performance (0.51 for ECOG0 vs 0.87 for ECOG1), less advanced disease (0.580 for stage IIB vs 0.705 for stage IV), histology (0.40 for Squamous NSCLC vs 0.69 for adeno NSCLC) and seems to be related to amount of chemotherapy received. No benefit was seen in nonresponders.

CADI-05 achieves and maintains remission in melanoma as well as in bladder cancer as a systemic monotherapy [90,91]. It achieves complete remission in muscle invasive bladder cancer when combined with radiotherapy which does not recur at least for two years [92].

It is approved in India for treatment of NSCLC and has orphan drug designation from US FDA for DSC3 expressing NSCLC.

B. Other Vaccine Candidates

I. Allogenic cell based vaccine

a. Gvax: An irradiated, syngeneic, GM-CSF-expressing tumor-cell vaccine (Gvax) has been shown to evoke dense intratumoral infiltrates of APCs displaying superior antigen-presenting activity. GVAX Pancreas induces large immunoglobulin G and immunoglobulin M responses to many antigens, including tumor-associated carbohydrates, blood group antigens, α-Gal, and bovine fetuin [93]. Gvax melanoma is associated with significant increases in eosinophils and PD-1+ lymphocytes from cycle 1 to cycle 4 (p<0.05) at vaccine site [b] Serum GM-CSF concentrations [a] increased numbers of activated circulating monocytes (p=0.0001) [c] decreased percentages of myeloid-derived suppressor cells among monocytes (CD14+ , CD11b+ , HLA-DR low or negative; p = 0.002) [94]. It failed when used as a standalone intervention against established tumors [95]. Phase III trials due to a lack of clinical efficacy. Among a myriad of potential reasons for this lack of success, one may be the presence of potent immune evasion mechanisms in established lesions. The failure could be attributed to inadequate immunogenicity of the approach and alterations in preparation of the vaccine product required by commercial scale-up [96]. Combination of a GVAX with an immune checkpoint blockade demonstrated no improvement over the blockade alone [97].

b. Belagenpumatucel-L: Belagenpumatucel-L is a therapeutic vaccine comprised of 4 transforming growth factor (TGF)-b2-antisense gene-modified, irradiated, allogeneic NSCLC cell, for maintenance therapy in NSCLC. In a phase III trial, 532 Patients with stable disease or response following up to 6 cycles of a platinum-based frontline chemotherapy regimen, with or without radiation therapy were randomized to receive maintenance belagenpumatucel-L (2.5 107 cells per dose) or placebo in a 1:1 ratio [98]. There was no difference in PFS (4.3 months versus 4.0 for belagenpumatucel-L vs placebo, respectively; HR 0.99, p = 0.947) or OS between the arms (median survival 20.3 versus 17.8 months with belagenpumatucel-L vs placebo, respectively; hazard ratio (HR) 0.94, p = 0.594). Time to randomization after end of chemotherapy had a significant impact on survival (p = 0.002). Benefit of treatment (HR 0.77, 95% CI 0.56–1.05; p = 0.092) was seen in those who were randomized within 12 weeks of the completion of frontline chemotherapy (median OS 20.7
months (95% CI 14.6–26.9) vs 13.4 months (95% CI 9.9–16.7). Prior chemora was a positive prognostic factor (median survival 28.4 months with belagenpumatucel-L versus 16.0 months with placebo; HR 0.61, p = 0.032).

c. **Canvaxin:** Canvaxin is an allogeneic whole-cell vaccine developed from three melanoma cell lines. It was evaluated in stage-IIl melanoma in a phase III trial [88]. It was discontinued based on the recommendation of the independent Data and Safety Monitoring Board (DSMB) with oversight responsibility for the clinical trial after review of the third interim analysis. Findings suggested it was unlikely that the trial would provide significant evidence of a survival benefit for Canvaxin-treated patients versus those receiving placebo. Trial evaluated three biomarker in peripheral blood MART-1, MAGE-A3 and PAX5 by measuring mRNA. Multivariate analysis suggest that absence of all three at base line as well as post treatment has better survival with HR for OS 1.53 (95% CI 1.05–2.24; p = 0.028), HR for PFS 1.64 (95% CI 1.19–2.24 p = 0.002) for pretreatment Number of biomarkers (+) > 0 vs 0. For post-treatment Number of biomarkers (+) > 0 vs 0 HR for OS was 2.57 (95% CI 1.23–5.36; p = 0.012) and for PFS was 1.91 (95% CI 1.11–3.; p=0.020).

II. **Protein/peptide based vaccines**

a. **IMA901:** IMA901, a vaccine consisting of ten tumor-associated peptides induces T-cell response. The IMPRINT study is an open-label, randomized, controlled, phase 3 trial [99]. 339 HLA-A*02-positive patients (aged ≥18 years) with treatment-naive, histologically confirmed metastatic or locally advanced (or both) clear-cell renal cell carcinoma were randomly assigned (3:2) to receive sunitinib plus IMA901 (4.13mg) and granulocyte macrophage colony-stimulating factor (75μg), with one dose of cyclophosphamide (300mg/m2) 3 days before the first vaccination (n=204), or to receive sunitinib alone (n=135). Sunitinib (50mg) was given orally once daily, with each cycle defined as 4 weeks on treatment followed by 2 weeks off treatment, until progression of disease. Median overall survival did not differ significantly between the groups (33•17 months [95% CI 27•81-41•36] in the sunitinib plus IMA901 group vs not reached [33•67-not reached] in the sunitinib monotherapy group; hazard ratio 1•34 [0•96-1•86]; p=0•087). IMA901 did not improve overall survival when added to sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

b. **Tecemotide:** The START trial randomized 1,513 patients with stage III NSCLC who had completed chemoradiotherapy without progressive disease to tecemotide (L-BLP25), a vaccine against MUC1 (a transmembrane mucin family protein), or placebo. There was no significant difference in survival between the two arms (median OS of 25.6 months with tecemotide versus 22.3 months with placebo). Benefit for the vaccine in patients who received concurrent rather than sequential chemotherapy (30.8 vs. 20.6 months, p=0.0175) [100].These promising results were not confirmed in a subsequent study [101] (median 32.4 versus 32.2 months, hazard ratio 0.95, 95% confidence interval 0.61-1.48; P=0.83).

c. **MAGE-A3 peptide based vaccine:** Vaccine to melanoma-associated antigen 3 (MAGE-A3) induces MAGE-A3 specific CD4+T cell response in some and MAGE-A3 specific CD8+T cell response in few patients with respected NSCLC in presence or absence of chemotherapy [102]. In the MAGRIT trial, patients with surgically resected stage IB-IIIA MAGE-A3-positive NSCLC were randomized to receive placebo or a vaccine to MAGE-A3. A total of 2,272 patients were randomized and treated. All patients in vaccine group achieved seropositivity for anti-MAGE-A3 antibodies indicating immune response to vaccine. The trial showed no significant improvement in disease-free survival (60.5 versus 57.9 months, p=0.7379) [103].

III. **Viral vector based vaccines**

a. **Tricom:** Tricom vaccine comprises of vaccinia and fowlpox viruses encoding prostate-specific antigen (PSA) along with three costimulatory molecules: B7.1, intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It demonstrated a benefit in overall survival without evidence of tumor shrinkage and change in progression-free survival (median survival of 25.1 months, vs 16.6-months, p= 0.015) in patients with castration-resistant prostate cancer [104].

b. **TG4010:** TG4010 is a recombinant modified vaccinia Ankara that codes for MUC1 and interleukin-2 [105]. MUC1 encoded by TG4010 shares epitopes with tumor-associated MUC1. It is being evaluated in the phase Iib/III trial The TIME trial in combination with first-line chemotherapy. It uses biomarker TrPal to measure baseline natural killer activity. Phase Iib part of the trial demonstrates survival benefit (PFS, OS) in non-squamous NSCLC having baseline TrPal value of less than or equal to the Q3 (123 patients of 222 enrolled). HR for PFS 0.59 (0.40-0.87) p = 0.0033 and OS 0.59(0.39-0.91) p=0.0072 [105].

**Conclusion**

Active immunotherapy holds promise for curing cancer if appropriately used along with other therapies to overcome tumor induced immune suppression and to alter hostile tumor micro environment. A recent advance in active immunotherapy has resulted in approval of T-Vec for melanoma as a monotherapy and CADI-05 for non-small cell lung cancer in combination with chemotherapy.

**References**


How to cite this article: Bakulesh K. Active Immunotherapy in cancer – Current Status. Nov Appro in Can Study. 1(3). NACS.000513.2018.

Volume 1 - Issue 3